Edition:
United Kingdom

IP Group PLC (IPO.L)

IPO.L on London Stock Exchange

72.50GBp
14 Jun 2019
Change (% chg)

-0.50 (-0.68%)
Prev Close
73.00
Open
71.00
Day's High
74.20
Day's Low
71.00
Volume
802,928
Avg. Vol
703,244
52-wk High
142.80
52-wk Low
70.20

Summary

Name Age Since Current Position

Douglas Flint

63 2018 Non-Executive Chairman of the Board

Alan Aubrey

57 2006 Chief Executive Officer, Executive Director

Greg Smith

40 2011 Chief Financial Officer, Executive Director

David Baynes

55 2014 Chief Operating Officer, Executive Director

Michael Townend

56 2011 Chief Investment Officer, Executive Director

Angela Leach

2008 Company Secretary

David Begg

68 2018 Senior Non-Executive Independent Director

Jonathan Brooks

63 2011 Non-Executive Independent Director

Heejae Chae

50 2018 Non-Executive Independent Director

Elaine Sullivan

58 2015 Non-Executive Independent Director

Biographies

Name Description

Douglas Flint

Sir Douglas J. Flint, CBE is Non-Executive Chairman of the Board of the Company, with effect from 01 November 2018. Sir Douglas was formerly Group Chairman of HSBC for 7 years, HSBC’s Group Finance Director for 15 years, Nonexecutive Director of BP plc for 6 years. He serves as Chairman of Standard Life Aberdeen plc, Chairman of the Just Finance Foundation, Director of the Centre for Policy Studies, sits on the Global Advisory Council of Motive Partners, Chairman of the Corporate Board of Cancer Research UK, a Trustee of the Royal Marsden Cancer Charity and Special Envoy to China’s Belt and Road Initiative.

Alan Aubrey

Mr. Alan John Aubrey is Chief Executive Officer, Executive Director of IP Group Plc. He co-founded Techtran Group Limited in 2002 and was its CEO when the business was acquired by IP Group in January 2005. Previously he was a partner in KPMG where he specialised in corporate finance advice to technology-based fast growth businesses and has an experience in helping them raise money and prepare for sale or flotation. Alan joined the Board of IP Group in January 2005, becoming Chief Executive on 1 January 2006 and has overall responsibility for the operational management of the Group. He is also a chairman of the Department for Business, Innovation & Skills (“BIS”) audit and risk committee.

Greg Smith

Mr. Greg Smith ACA., is Chief Financial Officer, Executive Director of IP Group plc., since June 3, 2011. He joined IP Group in January 2008 and was appointed Chief Financial Officer in June 2011. Previously Greg spent three years at Tarchon Capital Management, a multi-billion dollar fund of hedge funds business where he had day-to-day responsibility for building and managing the operations and accounting team as well as external operational due diligence on investee hedge funds. Prior to Tarchon, Greg spent four years in KPMG’s London Financial Services practice working with asset management, insurance and banking clients. Greg is Chartered Accountant and holds a degree in mathematics from the University of Warwick.

David Baynes

Mr. David Baynes is Chief Operating Officer, Director of IP Group PLC. He has 10 years as CEO at Fusion IP plc, previous experience taking companies from start-up to full listing on the London Stock Exchange

Michael Townend

Mr. Michael Charles Nettleton Townend is Chief Investment Officer, Executive Director of IP Group Plc. He was formerly managing director within the European Equities business of Lehman Brothers with responsibility for equity sales to hedge funds. Mike has over 17 years of experience in all aspects of equity capital markets. Mike was appointed a director of IP Group in March 2007.

Angela Leach

David Begg

Prof. David Knox Houston Begg is Senior Non-Executive Independent Director of the Company. He has Experience Professor of Economics at Imperial College London, Principal of Imperial College Business School 2003–2011. Previous appointments include Professor of Economics at Birkbeck College, Visiting Fellow at the Reserve Bank of Australia and Visiting Professor at M.I.T and acting as an economic policy adviser to the Bank of England

Jonathan Brooks

Mr. Jonathan Brooks is Non-Executive Independent Director of IP Group plc., since 31 August 2011. He was the chief financial officer of ARM Holdings plc from 1995 until 2002 where he was responsible for finance, investor relations, legal and IT, and where he managed the dual-listed IPO process of ARM on the London Stock Exchange and Nasdaq in 1998. He is a non-executive director of Aveva Group plc, a provider of engineering data and design IT systems, and chairman of Nasdaq-listed Xyratex Ltd, a provider of data storage systems. He joined IP Group’s Board in 2011 and is also Chairman of the Group’s Audit Committee.

Heejae Chae

Mr. Heejae Chae serves as Non-Executive Independent Director of the Company. He Current serves as CEO of Scapa Group plc, Former Group Chief Executive of Volex Group plc and Group General Manager for Amphenol Corporation. He is CEO of Scapa Group plc, Board of Overseers at Boston Children’s Hospital and an Advisory Council Member at Columbia University.

Elaine Sullivan

Dr. Elaine Sullivan is Non-Executive Independent Director of IP Group Plc., with effect from 30 July 2015. Dr Sullivan has over 25 years of international experience working in the pharmaceutical industry and was a member of the senior management teams in R&D at Eli Lilly and AstraZeneca. She has developed new molecules in therapy areas including virology, cancer, ophthalmology, respiratory and inflammation. In 2015, she founded a specialist oncology company, Carrick Therapeutics, and holds the position of Chief Executive. From 2011 to 2015, Dr Sullivan was Vice President Global External Research & Development in the US for Eli Lilly, where she led a global workforce delivering access to business critical external innovation. Global External R&D included the search and evaluation function and Chorus, the virtual early phase drug development arm. She was also a member of the Investment Committees of Lilly Ventures and Lilly Asian Ventures and a member of the Steering Committees of Lilly's Capital Fund Partners. Dr Sullivan spent over 15 years at AstraZeneca, where she held a number of roles including Vice President, Science & Technology. During this period, she identified and established novel drug-hunting approaches from target to delivery of proof of concept, which successfully reduced compound attrition in the clinic and significantly decreased the time to deliver new molecules. She also held the position of Vice President, R&D New Opportunities, establishing and leading the first virtual Therapy Area in AstraZeneca. New Opportunities pinpointed new disease areas and future healthcare trends, created new therapeutic applications for multiple molecular entities and advanced them into the clinic. Dr Sullivan has a BSc (Hons) in Molecular Biology from the University of Glasgow and a PhD in Molecular Virology from the University of Edinburgh. In June 2015, Dr Sullivan was appointed to the Supervisory Board of Evotec AG, a drug discovery solutions company.

Basic Compensation

Name Fiscal Year Total

Douglas Flint

50,000

Alan Aubrey

413,000

Greg Smith

352,000

David Baynes

366,000

Michael Townend

350,000

Angela Leach

--

David Begg

51,000

Jonathan Brooks

62,000

Heejae Chae

29,000

Elaine Sullivan

43,000
As Of  31 Dec 2018